Omega-3 and/or omega-6 fatty acid(s) in impaired sphingolipid metabolism
An application of omega-3 and/or omega-6 fatty acid(s) for the therapeutic treatment of the human or animal body in the case of an impaired sphingolipid metabolism, in particular in the case of impaired sphingolipid synthesis and/or excessive sphingolipid degradation. The agent is applied in the case of missing, reduced and/or defective formation of a sphingomyelin synthase enzyme in the body, in particular the enzyme sphingomyelin synthase 1 or the enzyme sphingomyelin synthase 2. The application has proved to be useful in the case of a defect of the sphingomyelin synthase 1 gene or of the sphingomyelin synthase 2 gene. The omega-3 and/or omega-6 fatty acid(s) preferably comprise(s) polyunsaturated omega-3 and/or omega-6 fatty acid(s), preferably EPA, DHA, DPA, ETA, 21:5n3 and/or SDA. A method for determining a cause of a disease in an animal or a human being and a device for carrying out the method are also provided.
1. A method for treating a human or animal having an impaired sphingolipid metabolism, the method comprising administering to the human or animal an effective amount of an omega-3 and/or omega-6 fatty add or an ester or a salt thereof, wherein the treatment is for Niemann-Pick disease, Tay-Sachs disease, Sandhoff disease, Tay-Sachs AB variant, Gaucher disease, Fabry disease, Krabbe disease, GM1 gangliosidosis, metachromatic leukodystrophy or fucosidosis.
2. The method according to claim 1 , wherein the impaired sphingolipid metabolism is due to impaired sphingolipid synthesis and/or excessive sphingolipid degradation.
3. The method according to claim 1 , wherein the impaired sphingolipid metabolism is due to a deficient, reduced and/or defective formation of sphingomyelin synthase 1 enzyme or sphingomyelin synthase 2 enzyme.
4. The method according to claim 1 , wherein the impaired sphingolipid metabolism is due to a deficient sphingolipid content in blood and/or in a testis.
5. The method according to claim 1 , wherein the impaired sphingolipid metabolism is due to a defect in the sphingomyelin synthase 1 gene and/or in the sphingomyelin synthase 2 gene.
6. The method according to claim 1 , wherein the omega-3 and/or omega-6 fatty acid comprises a multiply unsaturated omega-3 and/or omega-6 fatty acid.
7. The method according to claim 6 , wherein the omega-3 and/or omega-6 fatty acid comprises EPA, DHA, DPA, ETA, 21:5n3 and/or SDA.
8. The method according to claim 1 , wherein the omega-3 and/or omega-6 fatty acids are used as free fatty acids or in bound form.
9. The method according to claim 1 , wherein the omega-3 and/or omega-6 fatty acid are administered in a dosage of more than 0.5 g/day.
10. The method according to claim 1 , wherein the omega-3 and/or omega-6 fatty acid are administered in a dosage of 1 to 3 g/day.
11. The method according to claim 1 , wherein the treatment is for Niemann-Pick disease.
12. The method according to claim 1 , wherein the treatment is for Tay-Sachs disease.
13. The method according to claim 1 , wherein the treatment is for Sandhoff disease.
14. The method according to claim 1 , wherein the treatment is for Tay-Sachs AB variant.
15. The method according to claim 1 , wherein the treatment is for Gaucher disease.
16. The method according to claim 1 , wherein the treatment is for Fabry disease.
17. The method according to claim 1 , wherein the treatment is for Krabbe disease.
18. The method according to claim 1 , wherein the treatment is for GM1 gangliosidosis.
19. The method according to claim 1 , wherein the treatment is for metachromatic leukodystrophy.
20. The method according to claim 1 , wherein the treatment is for fucosidosis.